Sign In
Buy VTGN
$0.229
-0.0108 (-4.50%)
At Close: Jul 17, 2026
Vistagen to Present at Jefferies 2023 Global Healthcare Conference
04:30pm, Tuesday, 06'th Jun 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua
What to Look For When Finding Penny Stocks to Buy, 3 Tips
06:00am, Thursday, 23'rd Mar 2023
Use these tips for finding penny stocks to buy in 2023 The post What to Look For When Finding Penny Stocks to Buy, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt
VistaGen Therapeutics, Inc. (VTGN) Q3 2023 Earnings Call Transcript
11:20am, Friday, 10'th Feb 2023
VistaGen Therapeutics, Inc. (NASDAQ:VTGN ) Q3 2023 Earnings Conference Call February 7, 2023 5:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Exe
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
07:34pm, Tuesday, 07'th Feb 2023
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 16.67% and 41.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for th
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
09:09am, Monday, 06'th Feb 2023
SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety
The 3 Biggest Impacts on Penny Stocks Prices
06:00am, Wednesday, 01'st Feb 2023
These factors are the main causes of penny stocks price movement The post The 3 Biggest Impacts on Penny Stocks Prices appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock
3 Penny Stocks Under $1 To Watch This Week
02:27pm, Wednesday, 11'th Jan 2023
Penny Stocks To Watch Under $1 This Week. The post 3 Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
BioCryst (BCRX) Down as it Discontinues Developing PNH Drug
05:10pm, Friday, 16'th Dec 2022 Zacks Investment Research
BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.
Cytokinetics (CYTK) Up Despite Unfavorable FDA Committee Voting
03:12pm, Thursday, 15'th Dec 2022 Zacks Investment Research
Cytokinetics (CYTK) gets an unfavorable recommendation from CRDAC on omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction.
Top Mistakes Penny Stocks Investors Make When Starting Out
11:00am, Wednesday, 07'th Dec 2022 PennyStocks
Are you making these penny stocks trading mistakes?
The post Top Mistakes Penny Stocks Investors Make When Starting Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStoc
Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
06:31pm, Tuesday, 06'th Dec 2022 Benzinga
Gainers
Summit Therapeutics Inc. (NASDAQ: SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecif
What Makes VistaGen Therapeutics, Inc. (VTGN) a New Buy Stock
05:00pm, Tuesday, 15'th Nov 2022 Zacks Investment Research
VistaGen Therapeutics, Inc. (VTGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes VistaGen Therapeutics, Inc. (VTGN) a New Buy Stock
01:33pm, Tuesday, 15'th Nov 2022
VistaGen Therapeutics, Inc. (VTGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
11:45pm, Thursday, 10'th Nov 2022 Zacks Investment Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 0% and 388.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the
